Perrigo Company plc (NYSE:PRGO) Given Average Recommendation of “Hold” by Analysts

Perrigo Company plc (NYSE:PRGO) has earned a consensus rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.3333.

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Finally, Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRGO. California State Teachers Retirement System raised its position in Perrigo by 911.0% during the second quarter. California State Teachers Retirement System now owns 1,617,661 shares of the company’s stock valued at $155,694,000 after purchasing an additional 1,457,656 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of Perrigo during the 2nd quarter valued at about $211,000. Odyssean LLC lifted its position in Perrigo by 132.7% in the 2nd quarter. Odyssean LLC now owns 44,334 shares of the company’s stock worth $461,000 after buying an additional 25,282 shares during the last quarter. Syon Capital LLC purchased a new stake in Perrigo in the second quarter worth approximately $160,000. Finally, Parvin Asset Management LLC bought a new position in Perrigo during the second quarter valued at approximately $79,000. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Perrigo Price Performance

PRGO traded down $0.06 on Monday, hitting $14.19. 119,048 shares of the stock were exchanged, compared to its average volume of 3,141,171. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -1.13, a PEG ratio of 1.62 and a beta of 0.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.32 and a quick ratio of 1.32. Perrigo has a 12 month low of $9.23 and a 12 month high of $24.49. The business has a 50-day moving average of $11.07 and a two-hundred day moving average of $11.42.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the firm earned ($0.06) EPS. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts forecast that Perrigo will post 2.2 EPS for the current fiscal year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 8.2%. Perrigo’s dividend payout ratio is presently -9.27%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.